Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

belinostat 2Gemcitabine 2Fluorouracil 2venetoclax 1toripalimab 1tazemetostat 1resiquimod 1poly ICLC 1perifosine 1pazopanib 1ivosidenib 1envafolimab 1enasidenib 1durvalumab 1drozitumab 1birinapant 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Loperamide 1Leucovorin 1Irinotecan 1Immunotherapy 1Immune Checkpoint Inhibitors 1Imatinib Mesylate 1IPI-926 1IFL protocol 1Fentanyl 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Chondrosarcoma × Medicare Part B × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡